|
Prevalence of delta-like ligand 3 expression in small cell lung cancer. |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
Stock and Other Ownership Interests - Amgen |
Patents, Royalties, Other Intellectual Property - METHODS FOR TREATING DLL3-EXPRESSING CANCER S Application No.: 63/386,606 |
|
|
Research Funding - Amgen (Inst); Amgen (Inst); Bayer (Inst); Day One Biopharmaceuticals (Inst); Sanofi Pasteur (Inst); Star Therapeutics (Inst) |
|
|
Research Funding - Amgen (Inst); Sanofi (Inst); SpringWorks Therapeutics (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Amgen |
|
|
|
Stock and Other Ownership Interests - Amgen |
Honoraria - AstraZeneca; Bayer; Pfizer |
Consulting or Advisory Role - AstraZeneca; Bayer; Pfizer |
Research Funding - Pfizer (Inst) |
|
|
Research Funding - Amgen (Inst); Bayer (Inst); Day One Biopharmaceuticals (Inst); GRAIL (Inst); Sanofi Pasteur (Inst) |
|
|
|
Stock and Other Ownership Interests - Amgen |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst); Sanofi (Inst) |
Speakers' Bureau - AstraZeneca (Inst); Janssen (Inst); Lilly (Inst); Pfizer (Inst); Pfizer (Inst) |
Research Funding - Amgen (Inst) |